A study led by the Barcelona Institute for Global Health (ISGlobal) and Aarhus University shows that children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) ...
53 minutes ago
0
0
Not all cancer cells are the same, and neither are their responses to drugs. Finding the right drug for the right cancer cell is a long battle in drug development and in designing effective treatments. A new AI tool called ...
Cystic fibrosis, one of the most common genetic diseases in Switzerland, promotes chronic bacterial infections by impairing the protective barrier of the airways. Scientists at the University of Geneva (UNIGE) have discovered ...
6 hours ago
0
1
A new study published in The American Journal of Pathology provides new evidence that immune cells enter the retina via the body's standard pathway, identifying PECAM as the gatekeeper and neutrophils as proresolving mediators. ...
6 hours ago
0
2
Researchers at Texas A&M University's Naresh K. Vashisht College of Medicine have identified time-specific patterns of brain activity following ketamine treatment in older adults with treatment-resistant depression.
5 hours ago
0
0
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from ...
10 hours ago
0
1
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung ...
9 hours ago
0
6
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection ...
9 hours ago
0
4
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 ...
9 hours ago
0
3
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according ...
9 hours ago
0
3
